www.stocktitan.net
The Chemours Company Reports Second Quarter Results
The Chemours Company (NYSE: CC) reported Q2 2026 Net Sales of $1.59 billion, down 1% year-over-year, with a 4% volume decline partly offset by 2% higher pricing and a 1% currency benefit. Net loss attributable to Chemours narrowed to $274 million (‑$1.81 per diluted share) from a $380 million loss, reflecting legal and environmental reserves tied to settlements and ongoing litigation, partially offset by a gain on the Kuan Yin property sale.Adjusted Net Income was $64 million ($0.42 per share) and Adjusted EBITDA was $247 million, down 5% year-over-year but up 46% sequentially. Free Cash Flow rose to $114 million, a 128% increase, with Free Cash Flow Conversion of 46% and net leverage reduced to 4.4x. TSS delivered $213 million Adjusted EBITDA (+3%), TT benefited from about 5% year‑to‑date TiO2 price increases, and APM’s Performance Solutions Net Sales grew 8% year-over-year. Chemours paid down €230 million of term loan debt and, for full-year 2026, continues to expect Net Sales growth of 1%–5% and Adjusted EBITDA of $775–$825 million, with Free Cash Flow Conversion above 25% and year-end net leverage around 3.8x.